dismay of authors, we had no choice but to reject many good papers (including one of my own) in order to advance very best work. The adjudication of limited space by a journal editor, to paraphrase Holly Smith, is the art of providing an equitable distribution of poverty and gently nudging unhappy authors toward an equality of dissatisfaction, Talleyrand's definition of diplomacy. In this I am sure we succeeded.
Our authors and dedicated reviewers provided us with many moments of sober reflection and sometimes mirth; my particular favorites of the latter were the unexpected arrival of a 138-page rebuttal letter to reviewer comments (don't do that), the giddiness of receiving a startling new discovery in our inbox, initial submissions written in foreign languages, and summary conclusions over-reaching for that arcane transom of certainty. Likewise, many authors fretted over sharing more data supporting their very best ideas, forgetting the old axiom that if the ideas were really that good, one would still have to cram them down other people's throats to gain acceptance.
There has been much debate in recent years whether science in nephrology is on the decline, and by extension, JASN is just the healthiest horse in the glue factory. I don't agree. Everything we know about the kidney started somewhere in a laboratory, and nephrology is still a vast, provocative, and rich scientific discipline limited only by our ability to rapidly translate basic research to the bedside. More well-done clinical trials would clearly brighten our arc.
We wish Karl Nath and his new associate editors a prosperous journey into the future.
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